The initial success of Sildenafil undeniably revolutionized the pharmaceutical landscape, but investing in companies heavily reliant on off-patent versions presents a uncertain picture. Despite early profits were impressive, the end of patents and the rise of less expensive alternatives have weakened sales. Thus, a thorough analysis of present reve